Analytical Quality Group Developments January through April 2026
Recommendation

13-15 October 2026
Barcelona, Spain
Board Developments
- No changes to Board composition.
Board Meetings
- For 2026, three Board meetings were planned: March (online), July (online), and November during PharmaLab 2026 in Darmstadt.
- The first online Board meeting took place on 27 March 2026.
Guideline Developments
- The Board is still working on updates and revisions of existing guidelines (OOS Guideline from 2013; OOE/OOT Guideline from 2016; APLM Guideline from 2018; AIQ & SV Guideline from 2023).
- The current status was discussed during the Board meeting, and the timeline was specified in more detail.
Surveys
- The Group collected input via a short survey to support the revision and update of its guidance on Out-of-Specification (OOS) investigations.
- The survey started in February and closed in mid-April. A total of 169 responses have been received. The responses are currently being evaluated.
- A report is planned to make the results available to everyone in a summarized form.
Miscellaneous
- Newsletters were sent to the members of the Group in February and March.
- The Group will participate in PharmaLab 2026. A one-day track as well as a pre-conference session are planned. Planning activities were discussed during the Board meeting, further developed afterwards, and are now almost complete.
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


